In 2023, our medicines reached 284 million patients around the world. Still, many more people are lacking access to essential medicines and healthcare. We are committed to helping ensure that our medicines are accessible to as many patients as possible, irrespective of where they come from. We have therefore embarked on a journey to fundamentally shift the way we do business and reimagine how to expand access to critical healthcare innovations.
In late 2017, we committed to systematically integrate access strategies into how we research, develop and deliver our new medicines globally and established the Novartis Access Principles. These strategies include adopting innovative pricing and access models, refocusing research and development based on society’s healthcare needs, and supporting approaches to strengthen healthcare systems.
